StreetInsider.com News Articles

Form 8-K SAB Biotherapeutics, For: Oct 13

Tue, 13 Oct 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20261013/27177924.html

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Thu, 01 Oct 2026 08:30:00 -0400

MIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) being held October 9-11, 2026 in Philadelphia, PA. Presentations will include encore Phase 1 data for SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.

“We are proud to sponsor and participate in the inaugural Breakthrough T1D

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Thu, 01 Oct 2026 08:30:00 -0400

“We are proud to sponsor and participate in the inaugural Breakthrough T1D

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Thu, 01 Oct 2026 08:30:00 -0400

“We are proud to sponsor and participate in the inaugural Breakthrough T1D

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

Thu, 01 Oct 2026 08:30:00 -0400

“We are proud to sponsor and participate in the inaugural Breakthrough T1D

Form 4 SAB Biotherapeutics, For: Sep 17 Filed by: Kropotova Alexandra

Fri, 18 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260918/27080698.html

Form 424B3 SAB Biotherapeutics,

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961788.html

Form 424B3 SAB Biotherapeutics,

Fri, 21 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260821/26961788.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932857.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932857.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Caligan Partners LP

Fri, 14 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260814/26932257.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Caligan Partners LP

Fri, 14 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260814/26932257.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26930485.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Commodore Capital LP

Fri, 14 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26930485.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930464.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260814/26930464.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26927039.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:04:00 -0400

si-local-file:///var/storage/secattach/20260814/26927039.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26924142.html

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26924142.html

Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26911265.html

Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26911265.html

Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 10 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260810/26898383.html

Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 10 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260810/26898383.html

Form 10-Q SAB Biotherapeutics, For: Jun 30

Thu, 06 Aug 2026 07:57:00 -0400

si-local-file:///var/storage/secattach/20260806/26879045.html